lonafarnib has been researched along with pravastatin in 6 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (pravastatin) | Trials (pravastatin) | Recent Studies (post-2010) (pravastatin) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 3,575 | 1,036 | 816 |
| Protein | Taxonomy | lonafarnib (IC50) | pravastatin (IC50) |
|---|---|---|---|
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Homo sapiens (human) | 0.1452 | |
| Insulin receptor | Rattus norvegicus (Norway rat) | 0.0056 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.0056 | |
| 3-hydroxy-3-methylglutaryl-coenzyme A reductase | Rattus norvegicus (Norway rat) | 0.0254 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 3.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, K | 1 |
| Brazier, J; Brown, WT; Campbell, SE; D'Agostino, RB; Gordon, LB; Kieran, MW; Kleinman, ME; Massaro, J | 1 |
| Hisama, FM; Martin, GM; Oshima, J | 1 |
| Cleveland, RH; D'Agostino, RB; Dowton, AA; Gerhard-Herman, M; Gordon, CM; Gordon, LB; Greer, MM; Huh, SY; Kieran, MW; Kleinman, ME; Liang, MG; Littlefield, K; Massaro, J; Miller, DT; Nazarian, A; Quinn, N; Shappell, H; Silvera, VM; Smoot, LB; Snyder, BD; Ullrich, NJ | 1 |
| Baltrusaitis, K; Braddock, DT; Cleveland, RH; D'Agostino, RB; Gordon, CM; Gordon, LB; Kieran, MW; Kleinman, ME; Li, X; Liang, MG; Massaro, J; Snyder, B; Walters, M | 1 |
| Cabral, WA; Collins, FS; Cubria, MB; DuBose, A; Erdos, MR; Kamalapathy, P; Karim, L; Masoudi, A; Nazarian, A; Oftadeh, R; Snyder, BD; Suarez, S | 1 |
1 trial(s) available for lonafarnib and pravastatin
| Article | Year |
|---|---|
Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome.
Topics: Bone and Bones; Carotid Arteries; Child, Preschool; Diphosphonates; Drug Therapy, Combination; Female; Humans; Imidazoles; Infant; Male; Piperidines; Pravastatin; Progeria; Prospective Studies; Protein Prenylation; Pyridines; Zoledronic Acid | 2016 |
5 other study(ies) available for lonafarnib and pravastatin
| Article | Year |
|---|---|
Drug development for progeria yields insights into normal aging.
Topics: Aging; Child; Clinical Trials as Topic; Diphosphonates; Drug Discovery; Humans; Imidazoles; Lamin Type A; Mutation; Piperidines; Pravastatin; Progeria; Pyridines; Time Factors; Zoledronic Acid | 2013 |
Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome.
Topics: Adolescent; Adult; Alkyl and Aryl Transferases; Atherosclerosis; Cause of Death; Child; Child, Preschool; Clinical Trials as Topic; Cohort Studies; Dimethylallyltranstransferase; Diphosphonates; Drug Therapy, Combination; Female; Genes, Dominant; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Kaplan-Meier Estimate; Lamin Type A; Male; Multicenter Studies as Topic; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Proportional Hazards Models; Protein Precursors; Protein Prenylation; Pyridines; Treatment Outcome; Young Adult; Zoledronic Acid | 2014 |
An encouraging progress report on the treatment of progeria and its implications for atherogenesis.
Topics: Diphosphonates; Female; Humans; Imidazoles; Lamin Type A; Male; Nuclear Proteins; Piperidines; Pravastatin; Progeria; Protein Precursors; Protein Prenylation; Pyridines; Zoledronic Acid | 2014 |
Extraskeletal Calcifications in Hutchinson-Gilford Progeria Syndrome.
Topics: Calcinosis; Calcium; Child; Child, Preschool; Creatinine; Female; Fibroblast Growth Factor-23; Humans; In Vitro Techniques; Lamin Type A; Male; Parathyroid Hormone; Piperidines; Pravastatin; Progeria; Pyridines; Zoledronic Acid | 2019 |
Evaluation of musculoskeletal phenotype of the G608G progeria mouse model with lonafarnib, pravastatin, and zoledronic acid as treatment groups.
Topics: Aging; Animals; Bone and Bones; Bone Density Conservation Agents; Cartilage; Disease Models, Animal; Femur; Glycosaminoglycans; Joints; Lamin Type A; Mice; Mice, Transgenic; Mutation; Osteoarthritis; Phenotype; Piperidines; Pravastatin; Progeria; Protein Processing, Post-Translational; Pyridines; X-Ray Microtomography; Zoledronic Acid | 2020 |